- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on L-MYC and N-MYC Amplified Solid Tumors in New Zealand
Total 13 results
-
Monte Rosa Therapeutics, IncRecruitingNSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast CancerUnited States, Canada
-
Memorial Sloan Kettering Cancer CenterTesaro, Inc.RecruitingSolid Tumor | Solid Tumor, Adult | Rectal Adenocarcinoma | Clinical Stage: Stage II (T3-4, N-) | Stage III (Any T, N+)United States
-
Novartis PharmaceuticalsNantCell, Inc.TerminatedPIK3CA Mutated Advanced Solid Tumors | PIK3CA Amplified Advanced Solid TumorsSpain, Belgium, United States, Canada
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)WithdrawnRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Burkitt Lymphoma | Refractory Burkitt... and other conditionsUnited States
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBelgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands
-
National Cancer Institute (NCI)Active, not recruitingPlasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditionsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.Active, not recruitingDiffuse Large B-Cell Lymphoma | Plasmablastic Lymphoma | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Adult Burkitt Lymphoma | MYC Gene MutationUnited States
-
Prelude TherapeuticsCompletedSarcoma | Non-small Cell Lung Cancer | Castrate Resistant Prostate Cancer | Solid Tumors With Known MYC Amplification | Hormone Receptor Positive HER2 Negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedBurkitt Lymphoma | Plasmablastic Lymphoma | Diffuse Large B-cell Lymphoma, c-MYC PositiveUnited States
-
Calithera Biosciences, IncCompletedRenal Cell Carcinoma | Non Small Cell Lung Cancer | Mesothelioma | Solid Tumors | Triple-Negative Breast Cancer | Fumarate Hydratase (FH)-Deficient Tumors | Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) | Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal... and other conditionsUnited States
-
Incyte CorporationActive, not recruitingCervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)France, United States, Japan, Belgium, Australia
-
Kymera Therapeutics, Inc.RecruitingSolid Tumors | T-cell Prolymphocytic Leukemia (T-PLL) | Non Hodgkin Lymphoma (NHL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-Cell Lymphoma (CTCL) | Large Granular Lymphocytic Leukemia (LGL-L)United States
-
Incyte CorporationActive, not recruitingCervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditionsFinland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway